Literature DB >> 32223337

Purinergic Signaling Involvement in Thymosin β4-mediated Corneal Epithelial Cell Migration.

Heung-Mo Yang1,2, Shin Wook Kang3, Jihye Sung3, Kyeongsoon Kim3,4, Hynda Kleinman5.   

Abstract

Purpose: This study aimed to determine the effect of thymosin beta 4 (Tβ4) on human corneal epithelial cell migration and the downstream signaling pathways. Tβ4 has a role in tissue development, cell migration, inflammation, and wound healing. A previous study showed that Tβ4 directly binds to F0-F1 ATP synthase. Other studies reported the role of extracellular ATP and purinergic receptors in cell migration with several cell types. Despite advancing to the clinical stage for treatment of eye disorders, the effect of Tβ4 on human corneal epithelial cell (HCEC) migration and proliferation and the precise downstream signaling pathway(s) have not been identified.
Methods: Various concentrations of Tβ4 were tested in vitro on human corneal epithelial cell proliferation using the CCK-8 Kit and on cell migration using the gap closure migration assay. Additionally, ATP levels at various time points were determined using the ATP Lite One-Step Kit. The Fluo 8 NO Wash Calcium Assay Kit was used to measure the intracellular Ca2+ concentration after treatment with various concentrations of Tβ4. P2X7 inhibitors were tested on ATP signaling and migration. Total- and phospho-ERK1/2 levels were determined in western blot.
Results: Tβ4 enhanced HCEC proliferation and migration in a dose- and time-dependent manner. Moreover, these functions were related to increased extracellular ATP levels, intracellular Ca2+ influx, and ERK1/2 phosphorylation. Tβ4-mediated HCEC migration was inhibited by specific P2X7 purinergic receptor antagonists suggesting the role of this receptor in Tβ4-mediated human corneal epithelial cell migration. Conclusions: These results suggest that Tβ4-mediated HCEC proliferation and migration are associated with increased ATP levels, P2X7 R-mediated Ca2+ influx, and the ERK1/2 signaling pathway. This study begins to describe the mechanisms for Tβ4-mediated corneal healing and regeneration.

Entities:  

Keywords:  Human corneal epithelial cells; migration; proliferation; purinergic signaling; thymosin β4

Year:  2020        PMID: 32223337     DOI: 10.1080/02713683.2020.1748891

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  5 in total

Review 1.  Antimicrobial Peptide Expression at the Ocular Surface and Their Therapeutic Use in the Treatment of Microbial Keratitis.

Authors:  Allison H Shannon; Sara A Adelman; Erin A Hisey; Sanskruti S Potnis; Vanessa Rozo; Madeline W Yung; Jennifer Y Li; Christopher J Murphy; Sara M Thomasy; Brian C Leonard
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

Review 2.  The Role of Endogenous Antimicrobial Peptides in Modulating Innate Immunity of the Ocular Surface in Dry Eye Diseases.

Authors:  Youssof Eshac; Rachel L Redfern; Vinay Kumar Aakalu
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

3.  Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in Pseudomonas aeruginosa-Induced Keratitis.

Authors:  Yuxin Wang; Thomas W Carion; Abdul Shukkur Ebrahim; Gabriel Sosne; Elizabeth A Berger
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

Review 4.  Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies.

Authors:  Klaudia Maar; Roland Hetenyi; Szabolcs Maar; Gabor Faskerti; Daniel Hanna; Balint Lippai; Aniko Takatsy; Ildiko Bock-Marquette
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

5.  Acupuncture Regulates Serum Differentially Expressed Proteins in Patients with Chronic Atrophic Gastritis: A Quantitative iTRAQ Proteomics Study.

Authors:  Feng Li; Bai Yang; Yanan Liu; Tianying Tang; Cun Wang; Mei Li; Siyi Lv; Qin Qi; Huirong Liu; Zheng Shi; Huangan Wu; Xiaomei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-14       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.